
We’ve now seen multiple trends come to fruition at the intersection of bio and technology over the past decade: A Moore’s Law for bio, thanks to computation; machine learning and AI transforming many areas of bio pharma and healthcare; the ability to not just “read”, but “write”, to bio, including CRISPR (even in just a decade). We’re also seeing the rapid unbundling of care delivery as well now, driven by “the great unlock” — which includes the unbundling of the hospital (into decentralized communities, virtually, and more) and the movement towards value- or outcome-based care.
Driving this revolution has been a new breed and wave of founders and startups that merge the worlds of technology and bio — importantly, not just the old world of biotech (or a narrow definition of tech in bio as only “digital health”), but something much broader, bigger, and blending both worlds. In short, biology — enabled by technology — is eating the world. This has not only changed how we diagnose, treat, and manage disease, but has been changing the way we access, pay for, and deliver care in the healthcare system. It is now entering into manufacturing, food, and several other industries as well. Bio is becoming a part of everything.
This new era of industrialized bio — enabled by AI as well as an ongoing, foundational shift in biology from empirical science to more engineered approaches — will be the next industrial revolution in human history. And propelling it forward is an enormous new driving force, the novel coronavirus SARS-CoV-2, its ever-evolving strains, and the resulting COVID-19 disease pandemic and response — which I believe is analogous to our generation’s World War II (WW2). In other words: a massive global upheaval, but that later led to unprecedented innovation and significant new players.
As a result, we will now see the emergence of bio’s version of GAFA — playing off the “Google Amazon Facebook Apple” of the leading companies in computing, social, mobile — but for bio. And with it, a post-WW2/ post-Covid “Industrial Bio Complex”.
Over half a century ago, we saw the modern industrial revolution decades after the war. It began with advances that came out during or immediately after the war, in healthcare — like flu vaccines, commercial production of penicillin, and blood transfusion — to technology advances like jet engines, radar, microwaves, and electronic computing (most notably with ENIAC, one of the world’s first general-purpose computers). But it was innovations in mass manufacturing and automating production — of household items, cars, etc. — that happened decades after, in the 1970s, that led to the most recent industrial revolution with later advances in semiconductors, electronics, computing, AI, and more.
As with WW2, COVID has been a brutal wake-up call and shock to the global system. The mass casualties and horrors of this disease, as well as our ability to adapt and improve our response to it, will spur — has already spurred — a new wave of innovation, renewed energy, and vigor in the biopharma and healthcare industries. The world now sees both the why and the how behind the promise of engineering in healthcare; just take for instance the speed at which and way we developed the mRNA vaccines.
This is why I believe the equivalent tech revolution that follows our generation’s world war, post-Covid will be the creation of an Industrial Bio Complex — because the industrialization of bio brings new scale, and with it, new treatments, healthier lifestyles, new manufacturing and construction that reduces the effect of climate change, and more. Bio thus becomes the new manufacturing revolution, where everyone pours their attention, investment, education, and efforts: whether for safety and health, national security, or greater prosperity.
Artificial intelligence (AI) will continue to play a transformative role here. As with previous revolutions, this technology platform shift will impact industries differently. Notably, international scholar Carlota Perez has illustrated how the technologies of the next industrial revolutions are not necessarily an aid to the previous; for example, the tech revolution of the 1970s did not majorly impact the industrialization of 1940s and 1950s goods. Similarly, AI ironically will not have its greatest impact on the tech revolution. For areas where “compute” already dominates — that are already riding Moore’s Law — AI can be overhyped; and as Casado and Bornstein explain, AI does not necessarily make a massive contribution to those business models. [It is tempting to label AI itself as an industrial revolution, but as Perez further notes, the technologies themselves are not revolutions. Rather, industrial revolutions reflect the combination of multiple, transformative technologies into a specific, large potential market.]
In the bio and healthcare market, which is largely dominated by services, we would expect to see potentially massive gains from AI — at least to the extent that AI can transform services into “compute”. AI is not always as useful in enterprise because it is slower than the status quo, more expensive in terms of unit economics, etc. But in bio, AI can be extremely helpful: It helps turn the things that used to be expensive, human-labor intensive, less efficient, and less accessible, into less costly, more efficient, and even more effective “compute”.
Once that happens, technology can penetrate into the industries that previously did not benefit from the IT revolution. In fact, economists and innovators have long wondered why we haven’t seen the kinds of massive gains we’ve seen in other industries, in healthcare — aka Baumol’s Cost Disease — because when technology successfully penetrates industries, it transforms formerly expensive services into much more affordable goods. (And frees up human labor to work on more meaningful work, which is where it could help in healthcare. In other words, technology can make human healthcare more human.)
We are poised on this cusp today. Until now, healthcare and biotechnology have been heavily dominated by services — provided by expertly trained scientists and doctors — that algorithms could not replace, let alone add enough value, to make sense for companies to adopt them. But now, we are at the very beginning of a revolution where AI is industrializing biopharma and healthcare, and it is being applied to everything from drug design and diagnostics to healthcare delivery and back-office functions. [As for concerns or challenges that often come up with discussions of applying AI in bio, I address the “black box” of AI in healthcare here; and address what’s needed for us to get smart (vs. “dumb”) AI in bio, here.]
In all these areas (and others yet to be seen), the industrialization of biopharma and healthcare can go a long way. Instead of a person training in an apprenticeship-like way to do something, for instance, the machine learns those things. We can make copies trivially, which lets us scale expertise in the same manner as we spin up cloud-based servers: immediately, cheaply (compared to expert labor), and at immense scale. And this is not limited purely to compute: Automation and robotics similarly enables scale, as well as further enabling true reproducibility of biology in a way not previously possible — thus addressing one of the greatest weaknesses of “pre-industrialized” bio.
Bio can now scale, massively.
Drawing on lessons from the last two decades in tech, what would we expect to see for the next two decades in tech x bio? What happens as we move even more so into engineering biology, and what are the consequences of two mega trends — the industrialization of bio, plus the post-WW/ post-Covid effect — coming together?
Consider for instance the last decade of mobile, and the cycles of how innovation happens in technology. Referencing Carlota Perez’ influential work again: Mobile, like many technologies before it, had an “installation” phase that preceded a “deployment” phase. Perez’ concepts are summarized well here by Jerry Neumann, but basically, in the installation phase, capital flows to building the infrastructure that technological revolution needs; this installation phase also requires more push than pull, which is where go-to-market, partnerships, and other business development especially matters for bio startups here. Then, in the deployment phase of a particular technological revolution — which mobile reached after we passed 2.5+ billion smartphones on earth — companies often move towards expanding and consolidating their existing markets, not just creating them. In this phase, companies begin competing even more so on cost, usability, and scale; for mobile, the shift led to new questions, such as “what can we build as we stand on the shoulders of giants”? (The giants in that case being companies like Apple and Google.)
I expect tech x bio to follow a similar path. Right now, we are at the juncture of realizing we need the ability to engineer bio, and a fuller ability to engineer it (i.e., we’re still in the installation phase). In the tech industry, the analog period for the web led to the creation of massive companies like Amazon and Google. Given the power of the combined trends — and the scale of the challenges and massive market of healthcare — we should expect to similarly see the rise of a few potentially trillion-dollar companies at scale: the equivalent of a Bio GAFA, finally.
For tech x bio founders, this means their ambitions can be bigger and more attainable than ever, if they are able to execute. For the industry, it means ways to address the systemic and structural problems of healthcare, which are currently fragmented or consolidated in all the wrong ways (not to mention entrenched in legacy silos and structures that technology can re-route around). Most importantly, for all of us, the gains of the Industrial Bio Complex should lead to healthier, longer, and richer lives through greatly improved care and access, at lower cost.